Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Intangibles (2021 - 2025)

Historic Intangibles for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $15.5 million.

  • Kiniksa Pharmaceuticals International's Intangibles fell 606.06% to $15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year decrease of 606.06%. This contributed to the annual value of $16.2 million for FY2024, which is 1875.0% down from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's Intangibles is $15.5 million, which was down 606.06% from $15.8 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Intangibles registered a high of $20.0 million during Q1 2021, and its lowest value of $15.5 million during Q3 2025.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Intangibles had a median value of $20.0 million in 2021 and averaged $18.5 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Intangibles changed by 0.0% in 2022, and later plummeted by 1875.0% in 2024.
  • Kiniksa Pharmaceuticals International's Intangibles (Quarter) stood at $20.0 million in 2021, then changed by 0.0% to $20.0 million in 2022, then changed by 0.0% to $20.0 million in 2023, then decreased by 18.75% to $16.2 million in 2024, then fell by 4.62% to $15.5 million in 2025.
  • Its last three reported values are $15.5 million in Q3 2025, $15.8 million for Q2 2025, and $16.0 million during Q1 2025.